sarcosine has been researched along with gsk923295 in 13 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 11 (84.62) | 24.3611 |
2020's | 2 (15.38) | 2.80 |
Authors | Studies |
---|---|
Annan, RS; Belmont, LD; Bergnes, G; Brejc, K; Chua, PR; Copeland, RA; Cornwell, WD; Desai, R; Dhanak, D; Diamond, MA; Faucette, LF; Finer, JT; Garcia, C; Giardiniere, M; Gilmartin, AG; Greshock, JD; Huang, PS; Jackson, JR; Knight, SD; Lad, L; Lee, Y; Lichtsteiner, S; Luo, L; McNulty, DE; Morgans, DJ; Nevins, N; Qian, X; Sakowicz, R; Schauer, SP; Sun, CM; Sutton, D; Vidal, JD; Wood, KW; Wooster, RF; Zhang, S | 1 |
Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Lock, RB; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA; Wozniak, AW | 1 |
Botbyl, JD; Chung, V; Heath, EI; Holen, KD; Johnson, BM; Kirby, LC; Lampkin, TA; Lynch, KM; Schelman, WR | 1 |
Degenhardt, YY; Diskin, SJ; Haglund, E; Maris, JM; Mayes, PA; Moy, C; Toporovskya, Y; Wood, A; Wooster, R | 1 |
Aguiar, P; Barisic, M; Geley, S; Maiato, H | 1 |
Oleinikov, AV; Tcherniuk, SO | 1 |
Barisic, M; Grishchuk, EL; Janke, C; Magiera, MM; Maiato, H; Pereira, AL; Silva e Sousa, R; Tripathy, SK; Zaytsev, AV | 1 |
Bechi, B; Bennett, A; Procter, DJ; Taylor, SS; Thompson, S; Tighe, A | 1 |
Cai, XJ; Dai, Y; Tang, JC; Wei, SS; Wu, K; Xu, M; Zheng, X | 1 |
McClelland, SE; Tovini, L | 1 |
Ando, T; Asai, A; Ogo, N; Ohba, M; Sawada, JI; Yamane, M | 1 |
Kapoor, TM; Phua, DYZ; Pisa, R | 1 |
Barra, V; Cilluffo, D; Di Leonardo, A | 1 |
1 trial(s) available for sarcosine and gsk923295
Article | Year |
---|---|
First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer.
Topics: Adult; Aged; Antimitotic Agents; Bridged Bicyclo Compounds, Heterocyclic; Chromosomal Proteins, Non-Histone; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Sarcosine; Treatment Outcome; Young Adult | 2012 |
12 other study(ies) available for sarcosine and gsk923295
Article | Year |
---|---|
Antitumor activity of an allosteric inhibitor of centromere-associated protein-E.
Topics: Allosteric Site; Animals; Antineoplastic Agents; Binding Sites; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; Dogs; Drug Screening Assays, Antitumor; Humans; In Vitro Techniques; Kinesins; Mice; Microtubules; Mitosis; Models, Molecular; Molecular Structure; Sarcosine; Xenograft Model Antitumor Assays | 2010 |
Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.
Topics: Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; Female; Humans; Inhibitory Concentration 50; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Experimental; Sarcosine; Xenograft Model Antitumor Assays | 2012 |
Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chromosomal Proteins, Non-Histone; Colonic Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Irinotecan; Lung Neoplasms; M Phase Cell Cycle Checkpoints; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Neuroblastoma; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Sarcosine; Temozolomide | 2013 |
Kinetochore motors drive congression of peripheral polar chromosomes by overcoming random arm-ejection forces.
Topics: Aurora Kinase A; Aurora Kinase B; Benzamides; Benzazepines; Bridged Bicyclo Compounds, Heterocyclic; Cell Division; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; Chromosome Segregation; Cytoplasmic Dyneins; DNA-Binding Proteins; Dyneins; Humans; Kinesins; Kinetochores; Microtubules; Quinazolines; RNA Interference; RNA, Small Interfering; Sarcosine; Spindle Apparatus | 2014 |
Pgp efflux pump decreases the cytostatic effect of CENP-E inhibitor GSK923295.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Chromosomal Proteins, Non-Histone; Cytostatic Agents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Flow Cytometry; Humans; Immunoenzyme Techniques; Sarcoma; Sarcosine; Tumor Cells, Cultured; Uterine Neoplasms; Verapamil | 2015 |
Mitosis. Microtubule detyrosination guides chromosomes during mitosis.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; Chromosome Segregation; Humans; Microtubules; Mitosis; Molecular Imaging; Sarcosine; Spindle Apparatus; Tubulin; Tyrosine | 2015 |
Cenp-E inhibitor GSK923295: Novel synthetic route and use as a tool to generate aneuploidy.
Topics: Aneuploidy; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Chromosomal Proteins, Non-Histone; Chromosomes; DNA Damage; Flow Cytometry; HCT116 Cells; HeLa Cells; Humans; Kinesins; Mitosis; Phenotype; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; RNA Interference; Sarcosine; Spindle Apparatus | 2015 |
GSK923295 as a potential antihepatocellular carcinoma agent causing delay on liver regeneration after partial hepatectomy.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Chromosomal Proteins, Non-Histone; Electrophoresis, Polyacrylamide Gel; Female; Fluorescent Antibody Technique; Humans; Immunohistochemistry; Liver Neoplasms; Liver Regeneration; Mice; Mice, Inbred C57BL; Real-Time Polymerase Chain Reaction; Sarcosine; Xenograft Model Antitumor Assays | 2019 |
Impaired CENP-E Function Renders Large Chromosomes More Vulnerable to Congression Failure.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cells, Cultured; Chromosomal Proteins, Non-Histone; Chromosome Aberrations; Chromosomes; Humans; Sarcosine | 2019 |
Identification of benzo[d]pyrrolo[2,1-b]thiazole derivatives as CENP-E inhibitors.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle Checkpoints; Cell Proliferation; Chromosomal Proteins, Non-Histone; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HCT116 Cells; HeLa Cells; Humans; Molecular Structure; Sarcosine; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
Distinct Mechanisms of Resistance to a CENP-E Inhibitor Emerge in Near-Haploid and Diploid Cancer Cells.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Chromosomal Proteins, Non-Histone; Diploidy; Drug Resistance, Neoplasm; Haploidy; Heterozygote; Humans; Microscopy, Fluorescence; Mutagenesis, Site-Directed; Protein Domains; Recombinant Proteins; Sarcosine | 2020 |
P14
Topics: Aneuploidy; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; HCT116 Cells; Humans; Phenotype; Sarcosine; Tumor Suppressor Protein p14ARF | 2020 |